SEC Form 4 · accession 0001209191-19-007483
Denali Therapeutics Inc. · DNLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ryan J. Watts
Officer — President and CEO · Director
Period of report
Feb 1, 2019
Accepted (ET)
Feb 5, 2019 · 6:27 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001714899
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Feb 1, 2019 | S | 6,050 | $18.65 | D | 2,646,588 | I | See footnote |
| Common StockF4,F3 | Feb 4, 2019 | S | 3,200 | $18.49 | D | 2,643,388 | I | See footnote |
| Common StockF5,F3 | Feb 4, 2019 | S | 854 | $19.12 | D | 2,642,534 | I | See footnote |
| Common StockF6,F3 | Feb 5, 2019 | S | 8,230 | $18.83 | D | 2,634,304 | I | See footnote |
| Common Stock | holding | — | — | — | 12,505 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The sales reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan.
- F2The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.40 to $18.97 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F3The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.
- F4The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.00 to $18.95 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F5The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $19.04 to $19.23 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- F6The sale price reported in column 4 of Table I represents the weighted average sale price of the shares purchased ranging from $18.55 to $19.29 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.